Hot Investor Mandate 1: Global Pharma Firm Looks Worldwide for New Platforms in Cardio, Oncology, Metabolic Diseases, and More

31 Aug

A global pharmaceutical company headquartered in Japan is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. The firm is currently looking for partnering and in-licensing opportunities across the globe.
The firm is currently looking for innovative therapeutics targeting the following priority areas: thrombosis & thrombolysis, pain management, cardiovascular disease, CNS, and rare diseases. Other interest areas include metabolic diseases, oncology, organ fibrosis and NAFLD/NASH, neurology, immunology, and mitochondrial disease. The firm is open to biologics or molecular targets, with an increased interest in new platform technologies. The following areas are currently out of focus: diabetes, hypertension, dyslipidemia, psychiatric diseases, and immunodeficiency.

The firm partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: